Why Small Pharma Deserves Big-Pharma Quality (And How Lonza Delivers)

Small Orders, Big Standards: Why I Refuse to Lower the Bar

I'll say it straight: if your CDMO treats a 1 kg API order as less important than a 100 kg order, you're working with the wrong partner. I've been a quality compliance manager for over four years, reviewing roughly 200 unique deliverables a year—from raw material certificates to final product batch records. In Q1 2024 alone, I rejected 12% of first deliveries because of spec deviations. The vendor's common excuse? "It's a small batch, the tolerance is looser." That's nonsense. cGMP doesn't have a volume discount.

What cGMP Really Means for Small Pharma

Everyone talks about cGMP in pharma, but many still confuse it with a scale-dependent checklist. cGMP—current Good Manufacturing Practice—is a minimum standard, not a sliding scale. Whether you're making 10 tablets or 10 million, the same regulatory framework applies: validated processes, documented deviations, traceable raw materials. I don't have hard data on how many small biotechs fail because they accepted sub-par quality from a supplier, but my sense is it's a lot more than we admit.

It's tempting to think that a small batch doesn't need the same rigor. But let's be real: a single contaminated cell culture media batch can ruin weeks of research. That's why when I specify requirements for a client ordering RPMI-1640 or DMEM from Lonza, I insist on the same GMP grade they'd use for a commercial launch. Lonza's MEM formulation, for instance, is produced under validated protocols regardless of the order size. That's not a luxury—it's a baseline.

Why 'Small Customer' Shouldn't Mean 'Lower Priority'

I've seen this pattern from the other side too. A few years ago, we sourced propylene glycol from a major supplier—let's just say, not Lonza, but a company like LyondellBasell. The sales rep tried to push a less rigorous spec because our order was under 50 kg. I pushed back. The difference in purity levels (0.5% vs. 0.1% impurity) could affect our final formulation. We ended up paying a small premium, but the batch passed USP testing on the first try. The point is: quality is not a negotiable line item.

Now, I'm not saying every polyurethane and elastomer supplier needs to be FDA-inspected. But when you're in the pharmaceutical or biotech space, the bar is different. Small companies often don't have the leverage to demand GMP compliance. That's exactly why CDMOs like Lonza need to make it standard—not a special request.

The Real Risk of Cutting Corners

I weighed this risk myself a few months ago. We had a project for a novel cell culture medium (a custom RPMI-1640 variant). The client was a startup with a tiny budget. The upside of going with a non-GMP producer: saving about $2,000. The downside: one impurity could invalidate weeks of cell growth data. I kept asking myself: is $2,000 worth potentially delaying their IND filing by 6 months? Calculated the worst case: a full redo of experiments at $18,000. Best case: it works fine. The expected value said go for it, but the downside felt catastrophic. We chose GMP-grade from Lonza. The batch arrived with full documentation—every intermediate tested, every deviation explained. No regret.

Addressing the Obvious Pushback

Some will argue small orders can't justify the overhead of full GMP compliance. I've heard it from procurement managers: "Our margin on this order is thin, so we can't offer the same level of quality assurance." That's a business model problem, not a quality problem. A well-run CDMO with standardized processes can handle small batches without blowing up costs—because the infrastructure is already in place. Lonza, for example, operates multiple GMP facilities that serve everything from R&D trials to commercial production. The marginal cost of applying the same procedures to a 10 L fermenter isn't double—it's minimal.

And let's not pretend that small clients are charity cases. Today's 10 kg order might be next year's 100 kg contract. I've seen it happen multiple times. The vendors who treated my early $200 orders seriously are the ones I still use for $20,000 orders.

Bottom Line: cGMP Isn't Optional—For Anyone

So here's my final position: cGMP in pharma means exactly what it says—current, good, manufacturing practice—for every unit, every batch, every customer. If a CDMO tries to sell you lower standards because your volume is small, walk away. Lonza doesn't do that (or at least, they've never tried on my watch). Their GMP certifications apply across the board, from API manufacturing to cell culture media formulations. That's the kind of consistency that builds trust.

Small doesn't mean unimportant. It means potential. And potential deserves the same quality as reality.